Literature DB >> 12224507

Human cytomegalovirus inhibition of major histocompatibility complex transcription and interferon signal transduction.

D M Miller1, C M Cebulla, D D Sedmak.   

Abstract

Pathogens have evolved diverse mechanisms for escaping host innate and adaptive immunity. Viruses that maintain a persistent infection are particularly effective at disabling key arms of the host immune response. For example, the herpesviruses establish a persistent infection in human and animal hosts, in part through critical immunoevasive strategies. Cytomegalovirus, a beta-herpesvirus, impairs major histocompatibility complex (MHC) class I and class II antigen presentation by decreasing MHC expression on the surface of the infected cell, thus enabling infected cells to escape CD8+ and CD4+ T lymphocyte immunosurveillance. Moreover, cytomegalovirus blocks the interferon signal transduction pathway, thereby limiting the direct and indirect antiviral effects of the interferons. In this review, we focus on an emerging paradigm in which the effectiveness of viruses, particularly human cytomegalovirus, to escape antiviral immune responses is significantly enhanced by their ability to inhibit MHC transcription and interferon (IFN)-stimulated (JAK/STAT) signal transduction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12224507     DOI: 10.1007/978-3-642-59421-2_10

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  14 in total

1.  Human cytomegalovirus protein pp71 disrupts major histocompatibility complex class I cell surface expression.

Authors:  Joanne Trgovcich; Colleen Cebulla; Pete Zimmerman; Daniel D Sedmak
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta.

Authors:  Gretchen L Bentz; Renshui Liu; Angela M Hahn; Julia Shackelford; Joseph S Pagano
Journal:  Virology       Date:  2010-04-08       Impact factor: 3.616

3.  Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1.

Authors:  Angela M Hahn; Leslie E Huye; Shunbin Ning; Jennifer Webster-Cyriaque; Joseph S Pagano
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 4.  Cell Signaling Pathways That Regulate Antigen Presentation.

Authors:  Randy R Brutkiewicz
Journal:  J Immunol       Date:  2016-10-15       Impact factor: 5.422

Review 5.  Recent molecular insights into rickettsial pathogenesis and immunity.

Authors:  Sanjeev K Sahni; Hema P Narra; Abha Sahni; David H Walker
Journal:  Future Microbiol       Date:  2013-10       Impact factor: 3.165

6.  Characterization of the elements and proteins responsible for interferon-stimulated gene induction by human cytomegalovirus.

Authors:  Shaojun Yang; James Netterwald; Weijia Wang; Hua Zhu
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Gastrointestinal Infections Caused by Cytomegalovirus.

Authors:  David A. Bobak
Journal:  Curr Infect Dis Rep       Date:  2003-04       Impact factor: 3.725

8.  Reduced expression of gamma interferon in serum and marked lymphoid depletion induced by Porphyromonas gingivalis increase murine morbidity and mortality due to cytomegalovirus infection.

Authors:  Jacob Stern; Ela Shai; Batia Zaks; Amal Halabi; Yael Houri-Haddad; Lior Shapira; Aaron Palmon
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

9.  Inhibition of CD1 antigen presentation by human cytomegalovirus.

Authors:  Martin J Raftery; Manuel Hitzler; Florian Winau; Thomas Giese; Bodo Plachter; Stefan H E Kaufmann; Günther Schönrich
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

10.  Edmonston measles virus prevents increased cell surface expression of peptide-loaded major histocompatibility complex class II proteins in human peripheral monocytes.

Authors:  Mamadi Yilla; Carole Hickman; Marcia McGrew; Elizabeth Meade; William J Bellini
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.